Contributions
Abstract: P891
Type: Poster
Abstract Category: Clinical aspects of MS - 6 MS and gender
Background: Data regarding infertility treatment and live birth rates (LBRs) in women with multiple sclerosis (MS) compared with women without MS are lacking. This retrospective administrative claims database analysis compared LBRs between women with and without MS receiving either oral infertility medications only, defined as clomiphene and/or letrozole and no gonadotropin (Gn), or injectable medications for controlled ovarian stimulation (COS), defined as ≥1 Gn and an ovulation trigger, either human chorionic Gn or Gn-releasing hormone agonist.
Methods: IMS Health Real World Data Adjudicated Claims - US data were used to identify a cohort of US women with MS (ICD-9-CM diagnosis code: 340.xx), between the ages of 18 and 55 years, with a minimum of 1 year continuous insurance eligibility from 1/1/2006 to 31/12/2015. The number of women with MS treated with oral infertility medications meeting the eligibility criteria was 672. A comparator group of women without MS meeting the same eligibility criteria and treated with oral infertility medications was also identified (n=11,982). Propensity score matching controlled for baseline age, geographic region and index-year quarter (n=609 patients in each group). The number of women meeting the eligibility criteria and treated with injectable COS medications was 281 with MS and 4868 without MS. The number of patients in each group after propensity score matching was 268. LBRs between the matched samples were compared.
Results: The mean (standard deviation) duration of follow-up available for women treated with oral infertility medications was 4.41 (2.53) years for women with MS and 4.48 (2.60) years for women without MS. LBRs for women treated with oral infertility medications was similar in women with and without MS (32.18% vs 31.53%, respectively; p=0.8536). The mean duration of follow-up available for women treated with injectable COS medications was 4.29 (2.49) years for women with MS and 4.24 (2.46) years for women without MS. The difference in LBRs for women treated with injectable COS medications of 5.22% (44.03% vs 49.25% for women with and without MS, respectively; p=0.2603) did not reach statistical significance.
Conclusions: LBRs for women with MS receiving infertility treatments did not statistically significantly differ compared with women without MS receiving infertility treatments; however, further research in a larger patient population is warranted.
Disclosure: MKH received funding support from EMD Serono, Inc.*; received support for service on scientific advisory boards from Biogen, Genzyme Sanofi, Teva Neuroscience, and Novartis; and received research support from Genzyme Sanofi. NCE is an employee of Health Services Consulting Corporation. Health Services Consulting Corporation received funding from EMD Serono, Inc.* to run the analysis. BH and ALP are employees of EMD Serono, Inc., Rockland, MA, USA. *A business of Merck KGaA, Darmstadt, Germany.
Abstract: P891
Type: Poster
Abstract Category: Clinical aspects of MS - 6 MS and gender
Background: Data regarding infertility treatment and live birth rates (LBRs) in women with multiple sclerosis (MS) compared with women without MS are lacking. This retrospective administrative claims database analysis compared LBRs between women with and without MS receiving either oral infertility medications only, defined as clomiphene and/or letrozole and no gonadotropin (Gn), or injectable medications for controlled ovarian stimulation (COS), defined as ≥1 Gn and an ovulation trigger, either human chorionic Gn or Gn-releasing hormone agonist.
Methods: IMS Health Real World Data Adjudicated Claims - US data were used to identify a cohort of US women with MS (ICD-9-CM diagnosis code: 340.xx), between the ages of 18 and 55 years, with a minimum of 1 year continuous insurance eligibility from 1/1/2006 to 31/12/2015. The number of women with MS treated with oral infertility medications meeting the eligibility criteria was 672. A comparator group of women without MS meeting the same eligibility criteria and treated with oral infertility medications was also identified (n=11,982). Propensity score matching controlled for baseline age, geographic region and index-year quarter (n=609 patients in each group). The number of women meeting the eligibility criteria and treated with injectable COS medications was 281 with MS and 4868 without MS. The number of patients in each group after propensity score matching was 268. LBRs between the matched samples were compared.
Results: The mean (standard deviation) duration of follow-up available for women treated with oral infertility medications was 4.41 (2.53) years for women with MS and 4.48 (2.60) years for women without MS. LBRs for women treated with oral infertility medications was similar in women with and without MS (32.18% vs 31.53%, respectively; p=0.8536). The mean duration of follow-up available for women treated with injectable COS medications was 4.29 (2.49) years for women with MS and 4.24 (2.46) years for women without MS. The difference in LBRs for women treated with injectable COS medications of 5.22% (44.03% vs 49.25% for women with and without MS, respectively; p=0.2603) did not reach statistical significance.
Conclusions: LBRs for women with MS receiving infertility treatments did not statistically significantly differ compared with women without MS receiving infertility treatments; however, further research in a larger patient population is warranted.
Disclosure: MKH received funding support from EMD Serono, Inc.*; received support for service on scientific advisory boards from Biogen, Genzyme Sanofi, Teva Neuroscience, and Novartis; and received research support from Genzyme Sanofi. NCE is an employee of Health Services Consulting Corporation. Health Services Consulting Corporation received funding from EMD Serono, Inc.* to run the analysis. BH and ALP are employees of EMD Serono, Inc., Rockland, MA, USA. *A business of Merck KGaA, Darmstadt, Germany.